论文部分内容阅读
目的 比较明竹欣(Valacicolvir)综合疗法和阿昔洛韦(ACV)片剂及针剂联合激光治疗复发性尖锐湿疣的疗效和安全性。方法 将符合入选标准的150例复发性尖锐湿疣患者按其自愿随机分组,“明竹欣”组:口服“明竹欣”300mg,每天2次,共服14天;ACV片剂组:口服ACV200mg,每天5次,共服14天;ACV针组:静脉滴注ACV5mg/kg,每天3次,共7天。在服药疗程中段应用激光机清除所有病灶。激光治疗后第3、7、10、14天按PASI评分法进行评价,治疗结束后3个月及6个月各随访1次,记录复发情况。通过观察不良反应及治疗前后血尿常规、肝肾功能评价其安全性。结果 “明竹欣”组疗效与ACV针组相近(P>0.05),且明显高于ACV片剂组(P<0.01)。在总复发率方面,“明竹欣”组(0％)与ACV针组(4％)相近,而与ACV片剂组(33.33％)有显著差异(P<0.01)。结论 “明竹欣”综合疗法治疗复发性尖锐湿疣的疗效明显优于ACV片,不良反应少,服药更方便,患者依从性更好。“明竹欣”综合疗法是治疗复发性尖锐湿疣的安全有效方法。
Objective To compare the efficacy and safety of Valacicolvir combined with acyclovir (ACV) tablets and injection in the treatment of recurrent condyloma acuminatum. Methods A total of 150 patients with recurrent condyloma acuminatum who met the inclusion criteria were randomized according to their willingness. The patients in Mingzhuxin group were given “Mingzhuxin” 300mg twice daily for 14 days. ACV tablet group: 200mg ACV , 5 times a day for a total of 14 days; ACV needle group: intravenous infusion of ACV5mg / kg, 3 times a day for a total of 7 days. In the middle of medication medication laser machine to remove all lesions. On the 3rd, 7th, 10th, and 14th days after laser treatment, the patients were evaluated by PASI score method. At 3 and 6 months after the treatment, the patients were followed up for 1 time, and the recurrence was recorded. By observing the adverse reactions and before and after treatment of hematuria, liver and kidney function to evaluate its safety. Results The results of Mingzhuxin group were similar to those of ACV needle group (P> 0.05), and were significantly higher than that of ACV tablet group (P <0.01). In the total relapse rate, “Mingzhuxin” group (0%) was similar to ACV needle group (4%), but significantly different from ACV tablet group (33.33%) (P <0.01). Conclusion The treatment of recurrent condyloma acuminatum with “Mingzhuxin” therapy is superior to ACV tablets with less adverse reactions, more convenient medication and better patient compliance. “Ming Zhu Xin” integrated therapy is a safe and effective treatment of recurrent condyloma acuminata.